Reaction
Inappropriate Affect reporting signals
As of the last recalculation, Inappropriate Affect appears in 1,577 FAERS reports alongside 36 co-occurring drug terms. The strongest observed disproportionality signal is ARIPIPRAZOLE ORAL (PRR 16.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Aripiprazole Oral | 49 | 16.1 | 16.1 |
| Aripiprazole Orally Disintegrating | 49 | 16.1 | 16.1 |
| Cannabidiol | 26 | 14.9 | 14.9 |
| Venlafaxine | 70 | 13.5 | 13.5 |
| Risperidone | 123 | 13.2 | 13.2 |
| Atomoxetine Hydrochloride | 23 | 12.9 | 12.9 |
| Clobazam | 22 | 12.0 | 12.1 |
| Lithium Carbonate | 15 | 11.8 | 11.8 |
| Dronabinol | 7 | 11.5 | 11.5 |
| Paliperidone | 20 | 11.5 | 11.5 |
| Lisdexamfetamine Dimesylate | 28 | 11.4 | 11.4 |
| Asenapine Maleate | 7 | 10.7 | 10.7 |
| Sodium Oxybate | 49 | 10.1 | 10.1 |
| Haloperidol | 18 | 9.9 | 9.9 |
| Zonisamide | 11 | 9.9 | 9.9 |
| Lamotirigine | 52 | 9.9 | 9.9 |
| Lamotrigine Extended-Release | 52 | 9.9 | 9.9 |
| Lamotrigine Chewable Dispersible | 52 | 9.9 | 9.9 |
| Haloperidol Lactate | 18 | 9.7 | 9.7 |
| Aripiprazole | 83 | 9.4 | 9.4 |
| Divalproex Sodium | 32 | 9.2 | 9.2 |
| Vigabatrin | 10 | 9.1 | 9.1 |
| Olanzapine | 67 | 8.6 | 8.6 |
| Guanfacine | 5 | 8.4 | 8.4 |
| Paliperidone Palmitate | 18 | 7.5 | 7.5 |
| Oseltamivir Phosphate | 13 | 7.1 | 7.1 |
| Brivaracetam | 4 | 5.9 | 5.9 |
| Fremanezumab-Vfrm | 5 | 5.8 | 5.8 |
| Brexpiprazole | 7 | 5.6 | 5.6 |
| Lacosamide | 15 | 5.4 | 5.4 |
| Clozapine | 46 | 5.0 | 5.0 |
| Varenicline Tartrate | 27 | 4.5 | 4.5 |
| Lurasidone Hydrochloride | 7 | 4.4 | 4.4 |
| Botulinum Toxin Type A | 4 | 4.3 | 4.3 |
| Esketamine Hydrochloride | 5 | 3.7 | 3.7 |
| Galcanezumab-Gnlm | 5 | 2.1 | 2.1 |